Regulus Therapeutics is working with researchers from the University of California, San Diego School of Medicine to identify new microRNA therapeutics for the treatment of angiogenic diseases. Angiogenesis--the formation of new blood vessels--plays a major role in the severity of cancer, diabetes, macular degeneration, inflammatory disease and arthritis, according to the release. Researcher pairs Regulus' microRNA platform with the university's expertise in animal models of angiogenesis. The program has already received a UC Discovery Grant, which is awarded to promote universities/industry partnerships. Financial details of the deal were not disclosed.
"The objective of our collaborative work with Regulus is to advance these initial discoveries and discover additional microRNAs involved in angiogenic diseases," explained David A. Cheresh, Ph.D., professor of pathology in the UCSD School of Medicine.
- take a look at the Regulus release